in

Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing | Industry Analysis | Market Size

Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions

Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.”

The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes:

  • A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies.
  • An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).
  • An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups).
  • Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio).
  • A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs.
  • A discussion on the upcoming opportunities that are likely to impact the evolution of this market over the coming years.
  • A discussion on various steps involved in development operations of companion diagnostics
  • A comparative analysis of the needs of different stakeholders involved in the development of companion diagnostic products.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Request for Customization:

https://www.rootsanalysis.com/reports/253/request-customization.html 

Type of test

  • Laboratory Developed Tests (LDTs)
  • Companion Diagnostic Tests (CDx)

Type of disease indication

  • Breast cancer
  • Blood cancer
  • Colon / Colorectal cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer

Type of cancer biomarker 

  • TMB
  • MSI / MMR
  • TILs

Type of analytical technique

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Others

Key geographical regions 

  • North America
  • Europe
  • Japan
  • China
  • Australia

Key companies covered in the report

  • Foundation Medicine
  • NeoGenomics Laboratories
  • Novogene
  • Q2 Solutions
  • Personal Genome Diagnostics
  • Dr Lal PathLabs
  • Shenzhen Yuce Biotechnology

Enquiry before Purchasing: 

https://www.rootsanalysis.com/reports/253/request-sample.html

Please Visit Our Upcoming Reports

Gonorrhea: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

Non-Viral Drug Delivery Systems (Focus on Intracellular Technologies and Intracellular Biologics) Market

Lactose Intolerance: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

Helicobacter pylori (H. pylori) Infection: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

Cold Chain Logistics Market, Industry Trends and Global Forecasts, 2021-2030

This post was created with our nice and easy submission form. Create your post!

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Loading…

0

What do you think?

GRT The Graph | NMR Numeraire | OXT Orchid | NU NuCypher | ALPHA Alpha Finance Lab | BTC Bitcoin |

US House Passes $1.9 Trillion COVID-19 Relief Package, $1,400 Direct Check Provisions Included

US House Passes $1.9 Trillion COVID-19 Relief Package, $1,400 Direct Check Provisions Included